Women with Parkinson's disease are often diagnosed later than men, experience different symptoms, and may respond differently to standard treatments, yet their experiences have been largely absent from clinical research and drug development. This gender gap in Parkinson's care is now drawing serious attention from researchers and patient advocates working to ensure women's voices shape how the disease is studied and treated.

Why Are Women with Parkinson's Diagnosed Later Than Men?

Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain and the buildup of a misfolded protein called alpha-synuclein. While men are diagnosed more frequently with Parkinson's, this statistic doesn't tell the whole story about the disease's impact on women.

Women face several barriers to timely diagnosis. They may experience delays in getting evaluated by movement disorder specialists, have reduced access to specialized care, and receive less informal caregiving support from family members. Additionally, women often carry multiple caregiving responsibilities for spouses, children, grandchildren, and aging parents, which can cause their own symptoms to be minimized or quietly accommodated until the disease has already significantly affected their independence, employment, relationships, and emotional wellbeing.

How Do Women's Parkinson's Symptoms Differ from Men's?

The lived experience of Parkinson's differs between men and women in ways that clinical research has historically overlooked. Women may present with a greater burden of non-motor symptoms, which are symptoms beyond movement problems. These can include depression, anxiety, sleep disturbances, and cognitive changes that significantly impact daily functioning but are sometimes harder to recognize as part of Parkinson's disease.

Beyond symptom presentation, women may also respond differently to dopaminergic therapies, the standard medications that replace dopamine in the brain. Some research suggests women experience more levodopa-induced dyskinesia, a side effect where involuntary movements develop after long-term use of levodopa, the most effective treatment for Parkinson's motor symptoms. Women also have lower access to device-aided therapies such as deep brain stimulation, a surgical procedure that uses electrical impulses to help control movement symptoms. This means the same disease can translate into a completely different therapeutic journey for women, with distinct side effects and care needs.

How to Ensure Women's Parkinson's Care Reflects Their Real Lives

Improving outcomes for women with Parkinson's requires a fundamental shift in how research and clinical care are designed. Experts emphasize that precision medicine in Parkinson's will remain incomplete unless it includes women's lived experiences as central evidence.

• Enroll Adequate Numbers of Women: Clinical trials must recruit sufficient numbers of women participants so that results can be analyzed separately by sex, revealing whether treatments work differently for men and women.
• Analyze Outcomes by Sex: Researchers must examine how symptoms, treatment responses, and side effects differ between men and women rather than pooling all data together.
• Capture Hormonal and Reproductive History: Understanding a woman's menstrual history, pregnancy, menopause status, and hormone use can reveal how biological factors influence Parkinson's progression and treatment response.
• Prioritize Patient-Reported Outcomes: Research should measure what matters most to patients themselves, including quality of life, symptom burden, and functional independence, not just clinical test scores.
• Listen to Women's Voices: Patient engagement in research design and drug development ensures that studies address the real-world challenges women face, from caregiving demands to access barriers.

What Is the GEM-PD Initiative and How Does It Address These Gaps?

The Critical Path Institute (C-Path) and its Critical Path for Parkinson's (CPP) consortium are working to accelerate drug development by creating a collaborative space where industry, academia, patient organizations, data scientists, and regulators can work together on shared barriers that slow clinical trials. A major component of this effort is the CPP Integrated Parkinson's Database, which brings together anonymized patient-level data from 27 observational studies and clinical trials involving more than 15,000 participants.

This data infrastructure is crucial because Parkinson's is highly heterogeneous, meaning it presents differently across individuals. No single study can answer all the questions needed to improve trial design and identify which patients will benefit most from specific treatments. By pooling data from thousands of patients, researchers can build disease progression models, develop better clinical outcome measures, and identify biomarkers that help predict treatment response.

"If research and clinical care do not capture these differences, we risk designing trials, endpoints, digital measures, and treatment pathways that do not fully reflect women's real lives," explained Ragasudha Botta, Senior Scientific Director of the Critical Path for Parkinson's at the Critical Path Institute.

Ragasudha Botta, Senior Scientific Director, Critical Path for Parkinson's at the Critical Path Institute

The current treatment landscape for Parkinson's remains largely focused on symptom control rather than stopping the disease itself. Levodopa remains the most effective treatment for bradykinesia (slow movement) and other core motor symptoms, but long-term treatment is often complicated by wearing-off effects, dyskinesias, and other adverse effects. Researchers are moving toward therapies that target disease biology, including alpha-synuclein aggregation, mitochondrial dysfunction, and gene therapy approaches. However, no currently available treatment has been shown to definitively halt Parkinson's progression or prevent neurodegeneration.

The push to include women's experiences in Parkinson's research represents a broader recognition that precision medicine cannot be truly precise without understanding how sex and gender shape disease presentation and treatment response. As research continues to evolve, ensuring that women's voices are heard from the earliest stages of drug development may ultimately lead to better treatments and outcomes for all people living with Parkinson's disease.